Miami, FL -  If one day you should find yourself in a dermatologist’s office with a diagnosis of skin cancer, don’t be too surprised. Consider these statistics. Skin cancer is so common that two million cases are diagnosed annually and those numbers are rising at an alarming rate. Every year there are more cases of skin cancer diagnosed than colon, breast, lung and prostate cancers combined. More people have had skin cancer in the past 30 years than all other cancers combined. One in five of us will develop skin cancer in our lifetime. Of the two million cases found this year, 62,000 will be malignant in nature and potentially fatal. In fact, malignant melanoma cases have been steadily increasing over the past 10 years and show no sign of abating. As with all cancers, early detection and treatment is the key to survival.

Fortunately, there are ways to detect most non-melanoma skin cancers in early stages, when they are curable. Most basal cell and squamous cell carcinomas first appear as changes in the skin. The most common treatment is surgery. The surgeon removes the visible cancer as well as a good deal of normal tissue around the area. The normal tissue is excised because it is difficult to determine the boundaries of the cancerous cells. But this may not be an issue for long as innovative new technologymay be soonavailable that will aid surgeons and dermatologists in better delineating margins when excising basal and squamous cell cancers. 

LED Medical Diagnostics Inc. (OTCQX:LEDIF) (TXS V:LMD) (FSE: LME) announced today that it is expanding research of its tissue fluorescence visualization technology to cover dermatologic applications. LED Medical is confident that its technology of fluorescence visualization will enhance a surgeon’s success when removing skin cancer by defining the margins of the disease. Cancerous areas that may not have been visible to the naked eye will show up when fluorescence visualization technology is applied.  

Marketed under the VELscope® Vx brand, the company’s patented technology is well on its way to becoming the industry standard for the adjunctive dental screening process for oral cancer and other oral diseases. The device is in use by more than 13,000 dentists in 23 countries. Over 25 million oral screenings globally have potentially saved thousands of lives. LED Medical is eager to apply the same technology to skin cancer and other dermatological diseases. In a recurrence study in which Velscope was used to delineate oral cancer margins during surgery there was a 0 percent recurrence of the cancer compared to a 25 percent recurrence with non Velscope aided surgeries. With the power of VELscope directed towards skin cancer applications, thousands more lives could be saved and disfigurements from the disease minimized.

There are other companies, such as MELA Sciences Inc. (NASDAQ: MELA,) that market products used to detect skin cancer. No one has the market cornered. What it boils down to, (as far as sales are concerned) is the effectiveness of the technology involved, ease of use and cost. If a company’s product is well defined within those parameters, the device will sell.  

LED Medical’s VELscope Vx falls neatly into the slot. The technology is cutting edge and proven effective by literally millions of oral cancer screenings. The device is hand-held, easy to use and it is extremely cost effective. LED Medical also holds a patent on fluorescence visualization for dermatologic diagnosis. The company is actively leveraging its product beyond the dental vertical into the mainstream medical metric. LED Medical is also extremely proactive in raising cancer awareness. There is a very real altruistic side to this company. In the end, it’s simply common sense investing in an emerging growth rock star. 

NEW:  Feature your company on EmergingGrowth.com.  Find out how by filling out our referral form here…  http://emerginggrowth.com/recommend-a-company-to-feature-on-emerging-growth

About EmergingGrowth.com

By offering 100% original and unmatched content by the best financial reporters, writers and bloggers in the business, EmergingGrowth.com is emerging as a leading digital financial media portal. Its services provide users, subscribers and advertisers with a variety of content and tools through a range of online, social media, mobile and other mobile outlets.

Since its inception, EmergingGrowth.com has distinguished itself from other financial media companies with its sly approach to reading between the lines in order to locate that needle in the haystack.  Sign up today to see what EmergingGrowth.com has to offer.

Contact:
EmergingGrowth.com
info@EmergingGrowth.com
305-323-5687

Join our Linked in Group…  http://www.linkedin.com/groups/?gid=4650356&trk=hb_side_g

Like us on Facebook... http://www.facebook.com/pages/EmergingGrowthcom/474647062557938

Disclosure All information contained herein as well as on the EmergingGrowth.com website is obtained from sources believed to be reliable but not guaranteed to be accurate or all-inclusive. All material is for informational purposes only, is only the opinion of EmergingGrowth.com and should not be construed as an offer or solicitation to buy or sell securities. EmergingGrowth.com has received compensation for preparation and distribution of this piece.  Full details of which can be found here, http://emerginggrowth.com/special-ledif Please consult an investment professional before investing in anything viewed within.  When EmergingGrowth.com receives shares for compensation it intends to sell those shares.  In addition, Please make sure you read and understand the Terms of Use, Privacy Policy and the Disclosure posted on the EmergingGrowth.com website. Always remember that investing in securities such as the ones listed within are for high-risk tolerant individuals only and not the general public. Whether you are an experienced investor or not, you should always consult with a stockbroker, financial advisor, or similar before purchasing or selling any securities viewed on any emails sent from EmergingGrowth.com or its website.